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Age-related hearing loss (ARHL) is the most prevalent sensory deficit in the elderly. This 
progressive hearing impairment leads to social isolation and is also associated with co-
morbidities, such as frailty, falls and late-onset depression. Moreover, there is a growing 
evidence linking it with cognitive decline and increased risk of dementia. Given the large 
social and welfare burden that results from ARHL, and because ARHL is potentially a 
modifiable risk factor for dementia, there is an urgent need for therapeutic interventions to 
ameliorate age-related auditory decline. However, a prerequisite for design of therapies is 
knowledge of the underlying molecular mechanisms. Currently, our understanding of ARHL 
is very limited. Here, we review recent findings from research into ARHL from both human 
and animal studies, and discuss future prospects for advances in our understanding of  




Age-related hearing loss (ARHL), also known as presbycusis, is a complex disorder that 
results from the cumulative effects of aging on the auditory system. It is defined as a 
progressive, bilateral, symmetrical age-related sensorineural hearing loss which is most 
pronounced at the higher frequencies. ARHL is the most prevalent chronic sensory deficit 
experienced by older adults, with approximately half of adults in their seventh decade 
exhibiting hearing loss that is severe enough to affect communication (Agrawal et al. 2008), 
and is the third most common health condition affecting older adults after heart disease 
and arthritis (Collins 1997). While not life-threatening, this condition is associated with 
significant psychological and medical morbidity, including social isolation, frailty, depression 
and cognitive decline (Lin et al. 2011a; Lin et al. 2013; Kamil et al. 2016; Rutherford et al. 
2018). In addition to the health burden, there is also a significant economic cost associated 
with ARHL. Stucky et al. (2010) estimated in the year 2002 alone the combined direct 
medical and lost productivity costs attributable to hearing loss in adults aged ≥65-years in 
the United States was ~$9.5 billion. Taking into account the expected increases in life 
expectancy, it is estimated the annual cost will rise to ~$60 billion by 2030 (Stucky et al. 
 
 
2010). As such, the health, societal, and economic costs of ARHL are vast and ever 
increasing. However, compared with congenital and early-onset hearing loss, our 
understanding of the biochemical processes and molecular biology underlying this condition 
are limited. Historically, this may reflect an underappreciation of the condition due to the 
now outmoded assumption that ARHL is an unavoidable effect of aging, but it is also due to 
the practical considerations and difficulties associated with studying this chronic condition 
in older human patients. 
 
ARHL Pathology and Epidemiology 
Historical studies of post-mortem human temporal bones suggest ARHL involves a number 
of auditory structures: degeneration of the mechano-transducing cochlear inner and outer 
hair cells (sensory presbycusis); reduced function within the stria vascularis (strial 
presbycusis, also known as metabolic presbycusis); and, degeneration of the auditory nerve 
(neural presbycusis) (Schuknecht 1955; Schuknecht and Gacek 1993; Ohlemiller 2004). 
However, in reality it is likely most people with presbycusis will exhibit a “mixed” pathology. 
In addition to peripheral lesions it is also likely there will be changes occurring in central 
auditory pathways that contribute to the development and progression of ARHL. In this 
chapter, we will predominantly focus on what is known about the effects of aging in the 
peripheral auditory system. While degenerative changes within the cochlea arise as a 
consequence of cellular aging, they also reflect the cumulative effects of additional extrinsic 
factors throughout the life of the individual. As such, ARHL is considered a multifactorial 
disorder with underlying risk factors that can be divided into several categories: biological 
age, gender, ethnicity, environment (e.g., noise exposure, ototoxic medications), lifestyle 
(e.g., smoking, drinking, diet), health co-morbidities (e.g., hypertension, diabetes), and 
genetic predisposition (Yamasoba et al. 2013). Information pertaining to the epidemiology 
of ARHL has mostly arisen from large cohort studies, where audiometric testing has been 
undertaken as part of the evaluation (Brant and Fozard 1990; Gates et al. 1990; 
Cruickshanks et al. 2003; Agrawal et al. 2008; Gopinath et al. 2009). However, while it is 
often difficult to directly compare data across these studies, due to differences in cohort 
demographics and definitions of hearing loss, it is generally accepted that prevalence 
doubles with every decade of life from the second, through to the seventh, decade. Males 
are more likely to experience hearing loss than females of the same age, and African 
 
 
Americans show a decreased risk compared with white or Hispanic Americans (Lin et al. 
2011b). While these ethnic differences in hearing sensitivity are not fully understood, it is 
thought they might relate to differential lifetime exposure to noise or other environmental 
risk factors, or differences in melanin levels. Indeed, a study undertaken in albino mice 
reported that absence of strial melanin coincided with age-associated loss of marginal cells 
and endocochlear potential decline when compared with coisogenic pigmented mice 
(Ohlemiller et al. 2009).  
  
While noise exposure and ototoxic medications are able to independently cause hearing loss 
in an individual of any age, they are also extrinsic factors that can exacerbate progression of 
ARHL (Yang et al. 2015). In modern society, it can be difficult to avoid exposure to 
environmental noise, whether this is in the work place, e.g., factory workers and armed 
forces, or with the dramatic increase in the use of personal music devices. Moreover, if you 
are prescribed ototoxic antibiotics, or require cisplatin-based anti-cancer therapy, these 
risks are unavoidable. Conversely, lifestyle is an ARHL risk factor that is amenable to change. 
In a recent cross-sectional analysis, utilizing 164,770 adults aged between 40 and 69-years 
of age from the UK Biobank Resource, it was found that smoking and passive smoking were 
associated with increased odds of hearing loss, odds ratio (OR) 1.15 (95% confidence 
interval (CI) 1.09–1.21) and 1.28 (95% CI 1.21–1.35), respectively (Dawes et al. 2014). The 
authors of this study suggest the higher OR for passive smoking compared to smoking can 
be explained by smokers being compared to non-smokers which will include passive 
smokers and therefore may underestimate the effects of smoking. However, moderate 
alcohol consumption was associated with reduced odds of hearing loss, OR 0.61 (95% CI 
0.57–0.65) (Dawes et al. 2014), which is in alignment with previous studies reporting an 
association between moderate alcohol intake with better hearing (Popelka et al. 2000; 
Fransen et al. 2008; Gopinath et al. 2010). In a European multicentre study utilizing 4083 
subjects between 53 and 67 years, in addition to smoking they also found that high body 
mass index (BMI) correlated with hearing loss (Fransen et al. 2008). However, in a similar 
sized study undertaken in Korea, low BMI was found to be associated with hearing loss in 
adults (Lee et al. 2015). Another larger study investigating the weighted prevalence and 
associated factors of hearing impairment in ~16,000 Korean adults found that individuals 
with cardiovascular risk factors (e.g., hypertension, diabetes, smoking, increased serum 
 
 
cholesterol) are at risk of developing hearing impairment (Hong et al. 2015). Moreover, the 
Australian Blue Mountains Hearing Study found Type 2 diabetes was associated with 
prevalent hearing loss in older adults, OR 1.55 (95% CI, 1.11-2.17) after adjusting for 
multiple risk factors (Mitchell et al. 2009). A meta-analysis of the effect of either type 1 or 
type 2 diabetes on hearing found an increased prevalence of hearing loss in diabetics 
compared to non-diabetics, OR 2.15 (95% CI, 1.72-2.68) and this relationship was not 
related to the age of participants (n=20,194) (Horikawa et al. 2013). While detecting 
associations between hearing loss and particular lifestyle choices or medical co-morbidities 
can be revealed utilizing large population cohorts, it can be difficult to disentangle the direct 
contribution of individual risk factors from indirect effects on general health, and therefore 
establish a causal link. However, taken together, these data suggest that a healthy lifestyle, 
which includes moderate alcohol intake, may afford some protection against ARHL. 
  
Lastly, heritability studies among twins and longitudinal studies of family cohorts have 
shown that genetic predisposition forms a large and important risk factor for ARHL. Various 
studies report heritability indices of between 0.35 and 0.55 (Karlsson et al. 1997; Gates et al. 
1999; Christensen et al. 2001). Hence, given the difficulties of accessing human cochlear 
tissue for biochemical studies, and as with congenital deafness it is a genetic approach that 
is the most likely to provide insights into the molecular mechanisms that result in age 
related decline in hearing. Here, we summarise and discuss the progress in our 
understanding of ARHL genetics based on recent studies undertaken in humans and animals 
and highlight future perspectives. 
 
Insights into ARHL pathology from recent research: Human Genetics 
As a common sensory disorder and a complex disease with a mixture of genetic and 
environmental components ARHL is resistant to genetic analysis by traditional linkage 
analysis in families. In a disorder with high heterogeneity, small to moderate genetic risk 
variants, and a significant environmental impact a familial genetic approach is of limited use. 
Since the first successful genome wide association study (GWAS) conducted in age related 
macular degeneration was published in 2005 (Klein et al. 2005), much hope was raised that 
this cohort-based approach rather than family-based analysis could reveal the genetic 
susceptibilities underlying common complex diseases including ARHL. Several GWAS into 
 
 
adult hearing status or ARHL have now been published (Friedman et al. 2009; Van Laer et al. 
2010; Girotto et al. 2011; Nolan et al. 2013; Wolber et al. 2014; Fransen et al. 2015; 
Vuckovic et al. 2015; Hoffmann et al. 2016) (summarised in Table 1) and although many 
candidates have been linked to ARHL a lack of genome-wide findings that are significant and 
a poor replication of findings across these studies has limited their impact. One 
interpretation of these studies is that the heritability of ARHL has been overestimated or, 
alternatively, that there are thousands of rare variants in the population of small effect on 
ARHL risk which would be impossible to detect by GWAS (Fransen et al. 2015).  
 
There are, however, explanations for why common ARHL risk variants in the population may 
not have been detected in these studies. The power of GWAS to detect genetic risk factors 
relies primarily on two factors (Manolio et al. 2009; Eichler et al. 2010; Ku et al. 2010). 
Firstly, it is necessary to have a good phenotyping measure which is able to clearly delineate 
between patients and controls; ideally the measure would also stratify patients into sub-
phenotypes that are a result of the same underlying pathology. Secondly, GWAS require 
very large cohorts involving sample sizes in the thousands and tens of thousands (Spencer et 
al. 2009; Gibson 2010; Hong and Park 2012). For hearing as a phenotype this is problematic; 
a pure tone audiogram is the gold standard measure but this requires a trained audiologist, 
a quiet environment and a significant amount of time. Extrapolate that out to a sample size 
of 10,000 then it becomes extremely expensive to collect these data. Although it may be 
possible to collect large numbers of ARHL patients from clinics, the recruitment of age 
matched controls with “good hearing” is more difficult. A compromise therefore often has 
to be made between the quality of the hearing data collected and the sample size. This 
explains why many of the large, population-based, publicly-funded genetic cohorts have 
either not included hearing in the phenotypes collected, or have only collected self-reported 
questionnaire based data. This has meant that hearing GWAS cohort collections have had to 
be initiated from individual research groups which inevitably has limited the number and 
scale of the studies undertaken.  
 
Different approaches have been taken to defining a hearing phenotype in the GWAS 
performed to date. Some studies have performed a quantitative population based analysis, 
others utilized a case-control design. Various phenotype measures used include: defined 
 
 
frequency thresholds, speech-in-noise test and public health records for evidence of hearing 
aid prescription in order to define the phenotype (see Table 1). The cohorts also differ 
greatly in the age range studied. Given these varied parameters it is perhaps unsurprising 
that there is a lack of replication between individual GWAS. Compared to the samples sizes 
of recent successful GWAS in other disorders (see https://www.ebi.ac.uk/gwas/ ), the 
studies also have reduced power due to the smaller samples caused by the difficulties in 
collecting large datasets as discussed above. 
  
Despite these issues the GWAS performed have identified a set of candidates for further 
analysis, providing a first step towards knowledge of ARHL pathogenesis. The strongest of 
these candidates is GRM7, the gene encoding glutamate metabotropic receptor 7, a finding 
that has been replicated in several independent cohorts although not in all populations 
tested (Friedman et al. 2009; Van Laer et al. 2010; Newman et al. 2012; Luo et al. 2013). It is 
a G-coupled receptor activated by L-glutamate and its activation is associated with reduced 
release of the neurotransmitter. Since GRM7 is expressed in hair cells and spiral ganglion 
neurons, Friedman et al. (Friedman et al. 2009) suggested that a genetic variant in GRM7 
might alter ARHL susceptibility due to increased glutamate release at the synaptic 
connection between inner hair cells and auditory neurons, which could accumulate to toxic 
levels. A decline in the number and quality of synaptic connections between the sensory 
hair cells and auditory neurons is also thought to underlie  “hidden hearing loss”, an effect 
in which individuals with normal hearing thresholds still struggle to hear when in a noisy 
environment (Schaette and McAlpine 2011; Liberman 2015; Viana et al. 2015; Liberman and 
Kujawa 2017). Based on evidence from mice it has been suggested that this synaptopathy is 
a primary pathology in noise-induced hearing loss (NIHL) and ARHL (Viana et al. 2015; 
Liberman and Kujawa 2017). The odds ratio for the GRM7 variant most strongly linked to 
ARHL was 2.56 although the overall haplotype effect was estimated at 12.01 (Friedman et 
al. 2009). 
 
Single nucleotide polymorphisms (SNPs) at 2 other genetic loci were recently reported to be 
associated at genome wide significant levels in a study using electronic health records from 
6527 patients with a diagnosis of an ARHL related phenotype (Hoffmann et al. 2016). One 
variant is a missense SNP in TRIOBP, a gene encoding TRIO and f-actin binding protein, an 
 
 
actin cytoskeleton regulator. Nonsense and frameshift mutations in this gene underlie 
autosomal recessive deafness-28 (DFNB28, MIM#609823), which present as a severe to 
profound deafness with a prelingual onset (Riazuddin et al. 2006; Shahin et al. 2006). In 
addition, characterization of Triobp isoform-specific knockout mice identify a role for 
TRIOBP in the formation of cochlear hair cell stereocilia rootlets, which are required to 
provide mechanical rigidity to the stereocilia bundle (Kitajiri et al. 2010). The second variant 
is intergenic, between the ISG20 and ACAN genes encoding proteins involved in interferon 
signaling and an extracellular matrix component, respectively. In both cases the SNPs 
identified had only a very modest effect on risk of ARHL with odds ratios below 1.2 despite 
the genome wide significance (Hoffmann et al. 2016).  
Given the lack of genome wide significance in many of the studies carried out to date 
researchers have sought to find the true associations amongst the background of false 
associations below this statistical threshold by a variety of strategies. These have included 
pathway analysis to identify enrichment of genes from pathogenic pathways, prioritizing 
hits in known deafness genes, investigation of gene function in mutant mouse models and 
meta-analysis of data across cohorts. These methods have helped strengthen evidence for 
ESRRG, encoding Estrogen Related Receptor Gamma (Nolan et al. 2013) (mouse model), 
PCDH20 encoding Protocadherin 20 (Vuckovic et al. 2015), SLC28A3 encoding the nucleoside 
transporter, Solute Carrier Family 28 Member 3 (Vuckovic et al. 2015), and SIK3 encoding 
Salt-Inducible Kinase 3 (Wolber et al. 2014) (all meta-analysis) as having a role in adult 
hearing loss . However, given the known heterogeneity involved in congenital deafness 
(Bowl et al. 2017) the expectation is that variants in hundreds of genes contribute to ARHL. 
Therefore, there is still a great need for much larger genetic studies using GWAS or whole 
exome or genome sequencing with greater power to detect the relatively subtle effects.  
    
Insights into ARHL pathology from recent research: Animal models 
Given the difficulties described above of studying presbycusis in human cohorts, researchers 
have taken to using animal models in order help determine the pathogenesis and genetics 
associated with ARHL. While no one model organism faithfully displays all aspects of human 
presbycusis, insights relating to molecular and cellular determinants of cochlear aging have 
been obtained from studies undertaken in several species including chinchilla, gerbil, rat, 
and mouse. For example, studies in aged Mongolian gerbils have shown that from 36-
 
 
months of age they exhibit a mild (15–35 dB) threshold shift, which is most pronounced at 
the higher frequencies (Mills et al. 1990). Moreover, an identified decline in endocochlear 
potential (EP) with little sensory hair cell and neuron loss, led to them being classified as a 
model for a strial-based ARHL (Tarnowski et al. 1991; Schmiedt et al. 2002). The decline in 
EP was shown to correlate with strial capillary loss and changes to the structure of the 
marginal cells (Gratton and Schulte 1995; Gratton et al. 1997; Spicer and Schulte 2005). In 
particular, it is thought that oxidative damage to mitochondria within the strial marginal 
cells causes reduced ATP production, which in turn reduces Na+, K+ ATPase activity, leading 
to a reduced EP and elevated auditory thresholds (Spicer and Schulte 2005). 
 
ARHL studies in the rat have utilized the inbred Fischer 344 (F344) albino strain, of which 
there are two substrains (DuCrl and NHsd). The age-related hearing function and pathology 
exhibited by these two substrains are mostly similar, but there are some differences (Syka 
2010). F344 rats of both substrains develop a fast, progressive high-frequency hearing loss 
beginning at 1-year of age, which extends to the lower frequencies by 18-months of age 
(Popelar et al. 2003). In addition, these rats exhibit a gradual decline in DPOAE amplitudes 
beginning in young animals, such that by 12 to 18-months of age DPOAEs are no longer 
present (Popelar et al. 2006). However, old F344 rats have good preservation of inner and 
outer hair cells (except at the very apical and very basal regions of the cochlea) (Popelar et 
al. 2006; Bielefeld et al. 2008). They do show markedly reduced labelling for collagen fibres 
in the lateral wall [Stria vascularis (SV) and Spiral ligament (SL)] and fewer type IV fibrocytes 
in the SL when compared to younger F344 (Buckiova et al. 2006; Buckiova et al. 2007). 
Similar to the Mongolian gerbils, aged F344 rats have a less vascularized SV and exhibit 
degenerative changes within the marginal cell layer of the SV. A more recent study of 
outbred Wistar albino rats show they also develop a hearing loss similar in progression and 
magnitude to F344 (Alvarado et al. 2014).  
Similar to gerbils and rats, certain mouse strains also exhibit age-related cochlear 
pathologies that correspond to a ‘strial-type’ of human presbycusis suggested by 
Schuknecht (Schuknecht 1955; Schuknecht and Gacek 1993; Ohlemiller 2004). 
 
Mouse as a model for ARHL 
 
 
The mouse has become a robust and reliable mammalian model for aging research 
(Vanhooren and Libert 2013). The reasons for this include the ability to strictly control both 
intrinsic and extrinsic factors, e.g., genetic background, diet, environment and health status. 
In addition, mice have a short lifespan meaning the effects of age become apparent within a 
contracted time period. 
 
Some of the earliest research employing mice to investigate the genetics of ARHL involved 
the use of inbred strains. Certain strains have long been reported as having ‘good’ hearing 
into old age (e.g., CAST, CBA/CaJ, CBA/J, C3H/HeH), whereas others show a progressive 
decline in auditory function (e.g., BALB, C57BL/6, DBA/2J). Subsequent genetic mapping 
studies have defined around 20 loci that influence ARHL in laboratory strains of mice, and 
for four of these the underlying genetic lesions have been identified, designated as ahl 
alleles, i.e., Cdh23753A (ahl, cadherin-23), Csrs29358506-A (ahl4, citrate synthase ), Gipc3343A 
(ahl5, GIPC PDZ Domain Containing Family Member) and Fscn2R109H (ahl8, fascin actin-
bundling protein 2, retinal)  (Noben-Trauth et al. 2003; Shin et al. 2010; Charizopoulou et al. 
2011; Johnson et al. 2012; Ohlemiller et al. 2016). 
 
The commonly used C57BL/6 strains develop progressive high-frequency hearing loss due to 
a hypomorphic mutation within the cadherin 23 (Cdh23) gene, which encodes a component 
of the stereocilial tip-link required for gating of the mechanoelectrical transducer channel 
(Noben-Trauth et al. 2003; Siemens et al. 2004; Kazmierczak et al. 2007). C57BL/6J mice 
exhibit cochlear pathological changes that match the sensory, neural and strial prebycusis 
subtypes proposed by Schuknecht. Consistent with the hearing loss, which is evident from 
as early as 3-months of age, these mice progressively lose sensory hair cells (inner and 
outer) in an age-dependent manner proceeding from cochlear base to apex. They also show 
loss of basal spiral ganglion cells, loss of SL fibrocytes and thinning of the SV, although no 
progressive EP decline is observed at >24-months of age (Hequembourg and Liberman 2001; 
Ohlemiller 2006; Ohlemiller 2009). However, while this strain has been labelled as a model 
of age-related hearing loss, currently there is no convincing evidence associating variants in 




Utilized in forward genetic screens, the mouse has been an invaluable model organism for 
the discovery of genes required for hearing function, and mutations leading to congenital 
and early-onset hearing loss (Hrabe de Angelis et al. 2000; Nolan et al. 2000; Clark et al. 
2004; Bowl et al. 2017). Similar hypothesis-generating approaches would likely yield 
important insights to genes involved with ARHL, but such programmes require large 
numbers of mice to be bred, aged and phenotyped, and are therefore prohibitively 
expensive for an individual research group to undertake. Recently, at the MRC Harwell 
Institute a large-scale phenotype-driven screen for genes associated with age-related 
disease was undertaken in mice. Utilizing the chemical mutagen ENU, pedigrees of 
mutagenized mice were generated and subject to recurrent screens for phenotypes as they 
aged (Potter et al. 2016). Importantly, the phenotyping pipeline included Clickbox and 
Auditory Brainstem Response (ABR) tests to assess hearing function. From ~150 pedigrees 
tested, 27 were found to exhibit late-onset phenotypes, including several that displayed 
late-onset progressive hearing loss. Of these, 3 were reported to be caused by ENU-induced 
mutations within novel hearing loss genes (Slc4a10, Wars2, and Zfyve26, encoding solute 
carrier family 4 member 10, mitochondrial tryptophanyl tRNA synthetase 2 and zinc finger 
FYVE-type containing 26, respectively). This demonstrates phenotype-driven screens have 
the capacity to identify models of progressive and/or late-onset hearing loss, and the 
potential to elaborate upon the genetics of this condition. 
 
The mouse is the predominant model organism for studying mammalian auditory function 
(Bowl and Dawson 2015). In particular, the genetic concordance for mutations causing 
congenital and early-onset hearing loss is very high, in that genetic lesions identified in 
patients when modelled in the mouse cause hearing loss, and “hearing” genes discovered in 
the mouse are often found to harbour mutations in human deafness patients. At present, 
the concordance for ARHL genes is not so high. In a recent review, Ohlemiller et al. (2016) 
list around 50 mouse, and 20 human, candidate genes that have been proposed to influence 
ARHL and/or NIHL (Ohlemiller et al. 2016). Interestingly, only around one quarter of the 
proposed human ARHL genes overlap with proposed mouse ARHL genes. This could mean 
the remaining candidate human genes are not required for age-related auditory function in 
the mouse or, more likely, the mouse models for these genes may not have been fully 
characterized into old age. To fully elaborate upon the requirement of these genes, mice 
 
 
would not only need to be sufficiently aged, but they may also need to be challenged (e.g., 
with noise or secondary genetic alleles) in order to induce an auditory phenotype. 
Additionally, the genetic variants that increase risk of ARHL, unlike many of those that cause 
congenital deafness, may need to be studied in “knock-in” models of the human mutation, 
rather than knockout models. These concerns are particularly relevant for the validation of 
candidate genes arising from GWAS, the vast majority of which have not yet been followed 
up in mouse models (Table 1). A more integrated approach is required to both validate 
ARHL GWAS hits in animal models and also provide insights into the mechanisms underlying 
ARHL, see Figure 1. 
 
As additional mouse and human ARHL susceptibility alleles are identified it will be 
interesting to observe if they are ‘mild’ alleles of genes reported for congenital/early-onset, 
hearing loss, or if they are novel genes not previously linked with hearing loss. In particular, 
one might expect that ARHL susceptibility genes are likely to encode structural and 
homeostatic proteins, normally required for maintaining auditory cellular structure and 
function into old age, and that hypomorphic alleles of these genes will provide less 
resilience to environmental or lifestyle ARHL risk factors. Indeed, genes linked to 
metabolism of reactive oxygen species, antioxidant systems and mitochondrial function 
have been reported as ARHL susceptibility genes (McFadden et al. 1999; Ohlemiller et al. 
2000; Van Eyken et al. 2007; Someya et al. 2008). These genes are not inner ear specific, but 
instead have wide-spread expression and function in many cells throughout the body. 
Identifying why the ear is so susceptible to loss of these genes will be important for the 
design of therapeutic interventions. 
 
Future perspectives 
Rapid technical developments in genetics are providing researchers with more advanced 
tools applicable to common disease research. Whole genome sequencing or whole exome 
sequencing capture all variants present so, unlike GWAS, these approaches will be able to 
identify if there are many rare variants in genes that confer ARHL susceptibility. However, 
even with these new tools there is still a need of large cohorts to have sufficient power to 
detect ARHL genes. The UK Biobank study is a population based study involving over 
500,000 people between 40 and 69 years of age which recently released genotype data 
 
 
imputed to 90 million variants (Sudlow et al. 2015). Self-reported hearing data is available 
from all participants and a speech-in-noise test was completed in a subset of 188,000 
participants (Dawes et al. 2014). Completion of this UK Biobank GWAS analysis in such a 
large cohort should determine whether there are common variants within the population 
that play a role in ARHL. Certainly, failure to detect any such associations in a study with 
such great power would indicate that either there are many thousands of very rare variants 
responsible, or that the heritability of ARHL has been greatly overestimated. 
 
To date, the mouse has been under-utilized as a model organism for the study of human 
presbycusis. However, this likely reflects the paucity of strong candidate genes arising from 
human association studies together with the cost of aging cohorts of mice to detect late-
onset effects rather than the mouse not being a good model organism. As more 
genes/alleles are identified through GWAS and familial sequencing studies, future 
endeavours will certainly involve the generation and longitudinal phenotyping of mouse 
mutants carrying these exact genetic lesions. Recent advances in genome editing 
technologies such as CRISPR/Cas9 that now allow the generation of mice carrying specific 
point mutations without leaving a ‘footprint’ is a rapid, highly efficient and relatively 
inexpensive approach to take. Validation of human ARHL-causing mutations in the mouse, 
or other organisms, will provide a genetic diagnosis, but equally importantly these models 
will also provide the opportunity to study disease progression and ascertain the pathological 
changes occurring within the aging cochlea, something that is not possible in humans. This 
understanding is a prerequisite for the design of therapeutic interventions to ameliorate 
age-related auditory decline. In addition, validated models can also be utilized for preclinical 
studies to test the efficacy of new therapeutic approaches. However, before embarking on 
the generation of a genome edited knock-in it is important to consider the effect of the 
candidate human mutation in the context of the human sequence. Moreover, careful 
consideration should also be given to which inbred or outbred mouse strain is used to 
model a human genetic lesion, as a given knock-in mutation on one particular genetic 
background may or may not show penetrance compared to when tested on a different 





ARHL and dementia 
One of the most significant developments in our knowledge of ARHL aetiology over the last 
decade has been the emergence of hearing loss as a risk factor for developing dementia. A 
large number of studies have found a link between ARHL and cognitive decline, dementia 
and Alzheimer’s Disease with the hearing loss pre-dating and predicting subsequent clinical 
diagnosis of dementia (Lin et al. 2013; Gurgel et al. 2014; Wei et al. 2017; Jayakody et al. 
2018). There are several possible explanations for this association between the two 
morbidities and the resulting implications for our understanding of the mechanisms 
underlying the two diseases. The most widely proposed model suggests that the lack of 
auditory input and subsequent social isolation accelerates loss of cognitive function. 
Alternatively, it could be that in some individuals with ARHL, the hearing loss itself is an 
early manifestation of a pre-clinical cognitive decline; it is known that patients with 
dementia show pathological signs of decline for decades before a clinical diagnosis of 
dementia. Thirdly, there may be common pathological pathways involved in causing both 
disorders. Plausible pathways that have been linked to both pathologies include oxidative 
damage, inflammation, vascular function, mitochondrial dysfunction, glutamate 
excitotoxicity and RNA granule dysregulation (Towers et al. 2011; Wong and Ryan 2015; 
Ganguly et al. 2017; Maziuk et al. 2017; Du et al. 2018; Jayakody et al. 2018; Ridge and 
Kauwe 2018). It is also possible that more than one of these models is relevant and that, as 
well as common causative factors underlying hearing loss and cognitive decline with age, 
the resulting lack of auditory input accelerates the psychological consequences and hence 
the clinical impact of the pathology. Pertinent to this question some studies have found that 
treatment of hearing loss with hearing aids is able to prevent or lessen the speed of 
cognitive decline (Dawes et al. 2015; Mamo et al. 2017; Maharani et al. 2018), although 
further studies are required to establish this as a preventative strategy. A positive side effect 
of recent publicity about the link between mid-life hearing loss and the risk of dementia is 




Therapeutic Approaches to Treating or Preventing ARHL 
 
 
Given there is currently an insufficient understanding of the mechanisms involved in ARHL it 
is unsurprising that very few clinical trials to prevent or treat ARHL have taken place. In the 
absence of clear biological targets for drug development, pharmaceutical companies are 
reluctant to invest in expensive translational research despite the size of the potential 
market for an ARHL therapy. In addition, the design of clinical trials to assess efficacy of 
therapies for ARHL is problematic. The identification of a drug which could prevent or 
ameliorate further progression of a mild to moderate hearing loss is currently a more 
realistic prospect than a drug or therapy which can improve an existing hearing loss. 
However, to detect a significant effect on hearing loss clinical trials may need to follow 
participants for months or years making them long and consequently expensive to 
undertake. Despite these difficulties a number of clinical and pre-clinical trials with 
pharmacological therapies for adult hearing loss are underway. The results of these early 
trials, even if unsuccessful at identifying an efficacious therapy will be important in 
informing the design of future ARHL clinical trials. The first reported clinical trial designed to 
treat ARHL with a pharmacological agent was conducted by Pfizer and completed in 2013 
using PF-04958242, a positive allosteric modulator of the AMPA receptor, an ionotropic 
glutamate receptor (Bednar et al. 2015). The study was undertaken with 44 participants 
with ARHL over the age of 50, and no improvement in hearing thresholds was detected 1 
and 5 hours after a single dose. In the CLARITY-1 study sponsored by Autifony Therapeutics 
Ltd and completed in 2016, the effect of a modulator of voltage gated potassium gated 
channels, AUT00063, on the hearing of people over the age of 50 who had been diagnosed 
with ARHL was assessed (https://clinicaltrials.gov/ct2/show/NCT02345031). After a 4 week 
treatment period no improvement in hearing as assessed by a speech-in-noise test was 
identified (n=37) compared to the placebo group (n=39) at the end of the study. A much 
larger study involving 550 participants is due to be completed in 2021, assessing the effect 
of the acetylcholinesterase inhibitor, Huperzine A on hearing function and cognitive decline 
over a 3 year period (https://clinicaltrials.gov/ct2/show/NCT03101722). A number of other 
clinical trials are underway to investigate the effect of various therapies on mild to 
moderate hearing loss, including a Novartis Pharmaceuticals Phase I and II study using a 
gene therapy approach to deliver the pro-hair cell transcription factor ATOH1 to participants 
with severe to profound hearing loss, in an attempt to improve hearing by promoting 
regeneration of hair cells from supporting cells 
 
 
(https://clinicaltrials.gov/ct2/show/NCT02132130). There is some evidence this approach 
has been able to restore hearing in animal models of hearing loss (Izumikawa et al. 2005). 
Furthermore, studies with modulators of metabotropic glutamate receptor 7 in animal 
models of NIHL conducted by Pragma Therapeutics have demonstrated proof of concept 
and are progressing to pre-clinical trials. Although these and other studies are not 
specifically recruiting ARHL patients, the results are likely to have implications for all types 
of acquired hearing loss.  
 
Concluding remarks 
Compared to the major advances in the understanding of the genes and pathological 
mechanisms involved in congenital deafness our knowledge of ARHL is still limited. There 
are many challenges that remain in this field, but it should also be acknowledged that some 
advances have been made, including the identification of some strong candidate genes 
implicated in ARHL susceptibility. Progress is also signified by the first clinical trials for 
progressive adult hearing loss being undertaken. Although whole genome sequencing is 
becoming increasingly affordable and will be utilised in ARHL, a lack of adequate research 
funding to undertake studies with sufficient power is probably still the major barrier to 






Agrawal Y, Platz EA, Niparko JK. 2008. Prevalence of hearing loss and differences by 
demographic characteristics among US adults: data from the National Health and 
Nutrition Examination Survey, 1999-2004. Arch Intern Med 168: 1522-1530. 
Alvarado JC, Fuentes-Santamaria V, Gabaldon-Ull MC, Blanco JL, Juiz JM. 2014. Wistar rats: a 
forgotten model of age-related hearing loss. Front Aging Neurosci 6: 29. 
Bednar MM, DeMartinis N, Banerjee A, Bowditch S, Gaudreault F, Zumpano L, Lin FR. 2015. 
The Safety and Efficacy of PF-04958242 in Age-Related Sensorineural Hearing Loss: A 
Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 141: 607-613. 
Bielefeld EC, Coling D, Chen GD, Li M, Tanaka C, Hu BH, Henderson D. 2008. Age-related 
hearing loss in the Fischer 344/NHsd rat substrain. Hearing research 241: 26-33. 
Bowl MR, Dawson SJ. 2015. The mouse as a model for age-related hearing loss - a mini-review. 
Gerontology 61: 149-157. 
Bowl MR, Simon MM, Ingham NJ, Greenaway S, Santos L, Cater H, Taylor S, Mason J, 
Kurbatova N, Pearson S et al. 2017. A large scale hearing loss screen reveals an 
extensive unexplored genetic landscape for auditory dysfunction. Nature 
communications 8: 886. 
Brant LJ, Fozard JL. 1990. Age changes in pure-tone hearing thresholds in a longitudinal study 
of normal human aging. J Acoust Soc Am 88: 813-820. 
Buckiova D, Popelar J, Syka J. 2006. Collagen changes in the cochlea of aged Fischer 344 rats. 
Experimental gerontology 41: 296-302. 
-. 2007. Aging cochleas in the F344 rat: morphological and functional changes. Experimental 
gerontology 42: 629-638. 
Charizopoulou N, Lelli A, Schraders M, Ray K, Hildebrand MS, Ramesh A, Srisailapathy CR, 
Oostrik J, Admiraal RJ, Neely HR et al. 2011. Gipc3 mutations associated with 
audiogenic seizures and sensorineural hearing loss in mouse and human. Nature 
communications 2: 201. 
Christensen K, Frederiksen H, Hoffman HJ. 2001. Genetic and environmental influences on 
self-reported reduced hearing in the old and oldest old. Journal of the American 
Geriatrics Society 49: 1512-1517. 
Clark AT, Goldowitz D, Takahashi JS, Vitaterna MH, Siepka SM, Peters LL, Frankel WN, Carlson 
GA, Rossant J, Nadeau JH et al. 2004. Implementing large-scale ENU mutagenesis 
screens in North America. Genetica 122: 51-64. 
Collins JG. 1997. Prevalence of selected chronic conditions: United States, 1990-1992. Vital 
Health Stat 10: 1-89. 
Cruickshanks KJ, Tweed TS, Wiley TL, Klein BE, Klein R, Chappell R, Nondahl DM, Dalton DS. 
2003. The 5-year incidence and progression of hearing loss: the epidemiology of 
hearing loss study. Archives of otolaryngology--head & neck surgery 129: 1041-1046. 
Dawes P, Cruickshanks KJ, Moore DR, Edmondson-Jones M, McCormack A, Fortnum H, Munro 
KJ. 2014. Cigarette smoking, passive smoking, alcohol consumption, and hearing loss. 
Journal of the Association for Research in Otolaryngology : JARO 15: 663-674. 
Dawes P, Emsley R, Cruickshanks KJ, Moore DR, Fortnum H, Edmondson-Jones M, McCormack 
A, Munro KJ. 2015. Hearing loss and cognition: the role of hearing AIDS, social isolation 
and depression. PloS one 10: e0119616. 
 
 
Du X, Wang X, Geng M. 2018. Alzheimer's disease hypothesis and related therapies. Transl 
Neurodegener 7: 2. 
Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH, Nadeau JH. 2010. Missing heritability 
and strategies for finding the underlying causes of complex disease. Nat Rev Genet 11: 
446-450. 
Fransen E, Bonneux S, Corneveaux JJ, Schrauwen I, Di Berardino F, White CH, Ohmen JD, Van 
de Heyning P, Ambrosetti U, Huentelman MJ et al. 2015. Genome-wide association 
analysis demonstrates the highly polygenic character of age-related hearing 
impairment. European journal of human genetics : EJHG 23: 110-115. 
Fransen E, Topsakal V, Hendrickx JJ, Van Laer L, Huyghe JR, Van Eyken E, Lemkens N, Hannula 
S, Maki-Torkko E, Jensen M et al. 2008. Occupational noise, smoking, and a high body 
mass index are risk factors for age-related hearing impairment and moderate alcohol 
consumption is protective: a European population-based multicenter study. Journal 
of the Association for Research in Otolaryngology : JARO 9: 264-276; discussion 261-
263. 
Friedman RA, Van Laer L, Huentelman MJ, Sheth SS, Van Eyken E, Corneveaux JJ, Tembe WD, 
Halperin RF, Thorburn AQ, Thys S et al. 2009. GRM7 variants confer susceptibility to 
age-related hearing impairment. Human molecular genetics 18: 785-796. 
Ganguly G, Chakrabarti S, Chatterjee U, Saso L. 2017. Proteinopathy, oxidative stress and 
mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. 
Drug Des Devel Ther 11: 797-810. 
Gates GA, Cooper JC, Jr., Kannel WB, Miller NJ. 1990. Hearing in the elderly: the Framingham 
cohort, 1983-1985. Part I. Basic audiometric test results. Ear and hearing 11: 247-256. 
Gates GA, Couropmitree NN, Myers RH. 1999. Genetic associations in age-related hearing 
thresholds. Archives of otolaryngology--head & neck surgery 125: 654-659. 
Gibson G. 2010. Hints of hidden heritability in GWAS. Nature genetics 42: 558-560. 
Girotto G, Pirastu N, Sorice R, Biino G, Campbell H, d'Adamo AP, Hastie ND, Nutile T, Polasek 
O, Portas L et al. 2011. Hearing function and thresholds: a genome-wide association 
study in European isolated populations identifies new loci and pathways. Journal of 
medical genetics 48: 369-374. 
Gopinath B, Flood VM, McMahon CM, Burlutsky G, Smith W, Mitchell P. 2010. The effects of 
smoking and alcohol consumption on age-related hearing loss: the Blue Mountains 
Hearing Study. Ear and hearing 31: 277-282. 
Gopinath B, Rochtchina E, Wang JJ, Schneider J, Leeder SR, Mitchell P. 2009. Prevalence of 
age-related hearing loss in older adults: Blue Mountains Study. Arch Intern Med 169: 
415-416. 
Gratton MA, Schulte BA. 1995. Alterations in microvasculature are associated with atrophy of 
the stria vascularis in quiet-aged gerbils. Hearing research 82: 44-52. 
Gratton MA, Smyth BJ, Lam CF, Boettcher FA, Schmiedt RA. 1997. Decline in the endocochlear 
potential corresponds to decreased Na,K-ATPase activity in the lateral wall of quiet-
aged gerbils. Hearing research 108: 9-16. 
Gurgel RK, Ward PD, Schwartz S, Norton MC, Foster NL, Tschanz JT. 2014. Relationship of 
hearing loss and dementia: a prospective, population-based study. Otol Neurotol 35: 
775-781. 
Hequembourg S, Liberman MC. 2001. Spiral ligament pathology: a major aspect of age-related 
cochlear degeneration in C57BL/6 mice. Journal of the Association for Research in 
Otolaryngology : JARO 2: 118-129. 
 
 
Hoffmann TJ, Keats BJ, Yoshikawa N, Schaefer C, Risch N, Lustig LR. 2016. A Large Genome-
Wide Association Study of Age-Related Hearing Impairment Using Electronic Health 
Records. PLoS genetics 12: e1006371. 
Hong EP, Park JW. 2012. Sample size and statistical power calculation in genetic association 
studies. Genomics Inform 10: 117-122. 
Hong JW, Jeon JH, Ku CR, Noh JH, Yoo HJ, Kim DJ. 2015. The prevalence and factors associated 
with hearing impairment in the Korean adults: the 2010-2012 Korea National Health 
and Nutrition Examination Survey (observational study). Medicine (Baltimore) 94: 
e611. 
Horikawa C, Kodama S, Tanaka S, Fujihara K, Hirasawa R, Yachi Y, Shimano H, Yamada N, Saito 
K, Sone H. 2013. Diabetes and risk of hearing impairment in adults: a meta-analysis. J 
Clin Endocrinol Metab 98: 51-58. 
Hrabe de Angelis MH, Flaswinkel H, Fuchs H, Rathkolb B, Soewarto D, Marschall S, Heffner S, 
Pargent W, Wuensch K, Jung M et al. 2000. Genome-wide, large-scale production of 
mutant mice by ENU mutagenesis. Nature genetics 25: 444-447. 
Izumikawa M, Minoda R, Kawamoto K, Abrashkin KA, Swiderski DL, Dolan DF, Brough DE, 
Raphael Y. 2005. Auditory hair cell replacement and hearing improvement by Atoh1 
gene therapy in deaf mammals. Nat Med 11: 271-276. 
Jayakody DMP, Friedland PL, Martins RN, Sohrabi HR. 2018. Impact of Aging on the Auditory 
System and Related Cognitive Functions: A Narrative Review. Front Neurosci 12: 125. 
Johnson KR, Gagnon LH, Longo-Guess C, Kane KL. 2012. Association of a citrate synthase 
missense mutation with age-related hearing loss in A/J mice. Neurobiology of aging 
33: 1720-1729. 
Kamil RJ, Betz J, Powers BB, Pratt S, Kritchevsky S, Ayonayon HN, Harris TB, Helzner E, Deal JA, 
Martin K et al. 2016. Association of Hearing Impairment With Incident Frailty and Falls 
in Older Adults. J Aging Health 28: 644-660. 
Karlsson KK, Harris JR, Svartengren M. 1997. Description and primary results from an 
audiometric study of male twins. Ear and hearing 18: 114-120. 
Kazmierczak P, Sakaguchi H, Tokita J, Wilson-Kubalek EM, Milligan RA, Muller U, Kachar B. 
2007. Cadherin 23 and protocadherin 15 interact to form tip-link filaments in sensory 
hair cells. Nature 449: 87-91. 
Kitajiri S, Sakamoto T, Belyantseva IA, Goodyear RJ, Stepanyan R, Fujiwara I, Bird JE, Riazuddin 
S, Riazuddin S, Ahmed ZM et al. 2010. Actin-bundling protein TRIOBP forms resilient 
rootlets of hair cell stereocilia essential for hearing. Cell 141: 786-798. 
Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane 
SM, Mayne ST et al. 2005. Complement factor H polymorphism in age-related macular 
degeneration. Science 308: 385-389. 
Ku CS, Loy EY, Pawitan Y, Chia KS. 2010. The pursuit of genome-wide association studies: 
where are we now? J Hum Genet 55: 195-206. 
Lee JS, Choi HG, Jang JH, Sim S, Hong SK, Lee HJ, Park B, Kim HJ. 2015. Analysis of Predisposing 
Factors for Hearing Loss in Adults. J Korean Med Sci 30: 1175-1182. 
Liberman MC. 2015. HIDDEN HEARING LOSS. Scientific American 313: 48-53. 
Liberman MC, Kujawa SG. 2017. Cochlear synaptopathy in acquired sensorineural hearing 
loss: Manifestations and mechanisms. Hearing research 349: 138-147. 
Lin FR, Metter EJ, O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L. 2011a. Hearing loss and 
incident dementia. Arch Neurol 68: 214-220. 
 
 
Lin FR, Niparko JK, Ferrucci L. 2011b. Hearing loss prevalence in the United States. Archives of 
internal medicine 171: 1851-1852. 
Lin FR, Yaffe K, Xia J, Xue QL, Harris TB, Purchase-Helzner E, Satterfield S, Ayonayon HN, 
Ferrucci L, Simonsick EM et al. 2013. Hearing loss and cognitive decline in older adults. 
JAMA internal medicine 173: 293-299. 
Luo H, Yang T, Jin X, Pang X, Li J, Chai Y, Li L, Zhang Y, Zhang L, Zhang Z et al. 2013. Association 
of GRM7 variants with different phenotype patterns of age-related hearing 
impairment in an elderly male Han Chinese population. PloS one 8: e77153. 
Maharani A, Dawes P, Nazroo J, Tampubolon G, Pendleton N, group SE-CW. 2018. 
Longitudinal Relationship Between Hearing Aid Use and Cognitive Function in Older 
Americans. Journal of the American Geriatrics Society. 
Mamo SK, Nirmalasari O, Nieman CL, McNabney MK, Simpson A, Oh ES, Lin FR. 2017. Hearing 
Care Intervention for Persons with Dementia: A Pilot Study. Am J Geriatr Psychiatry 
25: 91-101. 
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos 
EM, Cardon LR, Chakravarti A et al. 2009. Finding the missing heritability of complex 
diseases. Nature 461: 747-753. 
Maziuk B, Ballance HI, Wolozin B. 2017. Dysregulation of RNA Binding Protein Aggregation in 
Neurodegenerative Disorders. Front Mol Neurosci 10: 89. 
McFadden SL, Ding D, Reaume AG, Flood DG, Salvi RJ. 1999. Age-related cochlear hair cell loss 
is enhanced in mice lacking copper/zinc superoxide dismutase. Neurobiology of aging 
20: 1-8. 
Mills JH, Schmiedt RA, Kulish LF. 1990. Age-related changes in auditory potentials of 
Mongolian gerbil. Hearing research 46: 201-210. 
Mitchell P, Gopinath B, McMahon CM, Rochtchina E, Wang JJ, Boyages SC, Leeder SR. 2009. 
Relationship of Type 2 diabetes to the prevalence, incidence and progression of age-
related hearing loss. Diabet Med 26: 483-488. 
Newman DL, Fisher LM, Ohmen J, Parody R, Fong CT, Frisina ST, Mapes F, Eddins DA, Robert 
Frisina D, Frisina RD et al. 2012. GRM7 variants associated with age-related hearing 
loss based on auditory perception. Hearing research 294: 125-132. 
Noben-Trauth K, Zheng QY, Johnson KR. 2003. Association of cadherin 23 with polygenic 
inheritance and genetic modification of sensorineural hearing loss. Nature genetics 
35: 21-23. 
Nolan LS, Maier H, Hermans-Borgmeyer I, Girotto G, Ecob R, Pirastu N, Cadge BA, Hubner C, 
Gasparini P, Strachan DP et al. 2013. Estrogen-related receptor gamma and hearing 
function: evidence of a role in humans and mice. Neurobiology of aging 34: 
2077.e2071-2079. 
Nolan PM, Peters J, Strivens M, Rogers D, Hagan J, Spurr N, Gray IC, Vizor L, Brooker D, 
Whitehill E et al. 2000. A systematic, genome-wide, phenotype-driven mutagenesis 
programme for gene function studies in the mouse. Nature genetics 25: 440-443. 
Ohlemiller KK. 2004. Age-related hearing loss: the status of Schuknecht's typology. Current 
opinion in otolaryngology & head and neck surgery 12: 439-443. 
-. 2006. Contributions of mouse models to understanding of age- and noise-related hearing 
loss. Brain research 1091: 89-102. 
-. 2009. Mechanisms and genes in human strial presbycusis from animal models. Brain 
research 1277: 70-83. 
 
 
Ohlemiller KK, Jones SM, Johnson KR. 2016. Application of Mouse Models to Research in 
Hearing and Balance. Journal of the Association for Research in Otolaryngology : JARO 
17: 493-523. 
Ohlemiller KK, McFadden SL, Ding DL, Lear PM, Ho YS. 2000. Targeted mutation of the gene 
for cellular glutathione peroxidase (Gpx1) increases noise-induced hearing loss in 
mice. Journal of the Association for Research in Otolaryngology : JARO 1: 243-254. 
Ohlemiller KK, Rice ME, Lett JM, Gagnon PM. 2009. Absence of strial melanin coincides with 
age-associated marginal cell loss and endocochlear potential decline. Hearing 
research 249: 1-14. 
Popelar J, Groh D, Mazelova J, Syka J. 2003. Cochlear function in young and adult Fischer 344 
rats. Hearing research 186: 75-84. 
Popelar J, Groh D, Pelanova J, Canlon B, Syka J. 2006. Age-related changes in cochlear and 
brainstem auditory functions in Fischer 344 rats. Neurobiology of aging 27: 490-500. 
Popelka MM, Cruickshanks KJ, Wiley TL, Tweed TS, Klein BE, Klein R, Nondahl DM. 2000. 
Moderate alcohol consumption and hearing loss: a protective effect. Journal of the 
American Geriatrics Society 48: 1273-1278. 
Potter PK, Bowl MR, Jeyarajan P, Wisby L, Blease A, Goldsworthy ME, Simon MM, Greenaway 
S, Michel V, Barnard A et al. 2016. Novel gene function revealed by mouse 
mutagenesis screens for models of age-related disease. Nature communications 7: 
12444. 
Riazuddin S, Khan SN, Ahmed ZM, Ghosh M, Caution K, Nazli S, Kabra M, Zafar AU, Chen K, 
Naz S et al. 2006. Mutations in TRIOBP, which encodes a putative cytoskeletal-
organizing protein, are associated with nonsyndromic recessive deafness. American 
journal of human genetics 78: 137-143. 
Ridge PG, Kauwe JSK. 2018. Mitochondria and Alzheimer's Disease: the Role of Mitochondrial 
Genetic Variation. Curr Genet Med Rep 6: 1-10. 
Rutherford BR, Brewster K, Golub JS, Kim AH, Roose SP. 2018. Sensation and Psychiatry: 
Linking Age-Related Hearing Loss to Late-Life Depression and Cognitive Decline. Am J 
Psychiatry 175: 215-224. 
Schaette R, McAlpine D. 2011. Tinnitus with a normal audiogram: physiological evidence for 
hidden hearing loss and computational model. J Neurosci 31: 13452-13457. 
Schmiedt RA, Lang H, Okamura HO, Schulte BA. 2002. Effects of furosemide applied 
chronically to the round window: a model of metabolic presbyacusis. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 22: 9643-9650. 
Schuknecht HF. 1955. Presbycusis. The Laryngoscope 65: 402-419. 
Schuknecht HF, Gacek MR. 1993. Cochlear pathology in presbycusis. The Annals of otology, 
rhinology, and laryngology 102: 1-16. 
Shahin H, Walsh T, Sobe T, Abu Sa'ed J, Abu Rayan A, Lynch ED, Lee MK, Avraham KB, King 
MC, Kanaan M. 2006. Mutations in a novel isoform of TRIOBP that encodes a 
filamentous-actin binding protein are responsible for DFNB28 recessive nonsyndromic 
hearing loss. American journal of human genetics 78: 144-152. 
Shin JB, Longo-Guess CM, Gagnon LH, Saylor KW, Dumont RA, Spinelli KJ, Pagana JM, 
Wilmarth PA, David LL, Gillespie PG et al. 2010. The R109H variant of fascin-2, a 
developmentally regulated actin crosslinker in hair-cell stereocilia, underlies early-
onset hearing loss of DBA/2J mice. The Journal of neuroscience : the official journal of 
the Society for Neuroscience 30: 9683-9694. 
 
 
Siemens J, Lillo C, Dumont RA, Reynolds A, Williams DS, Gillespie PG, Muller U. 2004. Cadherin 
23 is a component of the tip link in hair-cell stereocilia. Nature 428: 950-955. 
Someya S, Yamasoba T, Kujoth GC, Pugh TD, Weindruch R, Tanokura M, Prolla TA. 2008. The 
role of mtDNA mutations in the pathogenesis of age-related hearing loss in mice 
carrying a mutator DNA polymerase gamma. Neurobiology of aging 29: 1080-1092. 
Spencer CC, Su Z, Donnelly P, Marchini J. 2009. Designing genome-wide association studies: 
sample size, power, imputation, and the choice of genotyping chip. PLoS genetics 5: 
e1000477. 
Spicer SS, Schulte BA. 2005. Pathologic changes of presbycusis begin in secondary processes 
and spread to primary processes of strial marginal cells. Hearing research 205: 225-
240. 
Stucky SR, Wolf KE, Kuo T. 2010. The economic effect of age-related hearing loss: national, 
state, and local estimates, 2002 and 2030. Journal of the American Geriatrics Society 
58: 618-619. 
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, 
Landray M et al. 2015. UK biobank: an open access resource for identifying the causes 
of a wide range of complex diseases of middle and old age. PLoS Med 12: e1001779. 
Syka J. 2010. The Fischer 344 rat as a model of presbycusis. Hearing research 264: 70-78. 
Tarnowski BI, Schmiedt RA, Hellstrom LI, Lee FS, Adams JC. 1991. Age-related changes in 
cochleas of mongolian gerbils. Hearing research 54: 123-134. 
Towers ER, Kelly JJ, Sud R, Gale JE, Dawson SJ. 2011. Caprin-1 is a target of the deafness gene 
Pou4f3 and is recruited to stress granules in cochlear hair cells in response to ototoxic 
damage. J Cell Sci 124: 1145-1155. 
Van Eyken E, Van Camp G, Fransen E, Topsakal V, Hendrickx JJ, Demeester K, Van de Heyning 
P, Maki-Torkko E, Hannula S, Sorri M et al. 2007. Contribution of the N-
acetyltransferase 2 polymorphism NAT2*6A to age-related hearing impairment. 
Journal of medical genetics 44: 570-578. 
Van Laer L, Huyghe JR, Hannula S, Van Eyken E, Stephan DA, Maki-Torkko E, Aikio P, Fransen 
E, Lysholm-Bernacchi A, Sorri M et al. 2010. A genome-wide association study for age-
related hearing impairment in the Saami. European journal of human genetics : EJHG 
18: 685-693. 
Vanhooren V, Libert C. 2013. The mouse as a model organism in aging research: usefulness, 
pitfalls and possibilities. Ageing research reviews 12: 8-21. 
Viana LM, O'Malley JT, Burgess BJ, Jones DD, Oliveira CA, Santos F, Merchant SN, Liberman 
LD, Liberman MC. 2015. Cochlear neuropathy in human presbycusis: Confocal analysis 
of hidden hearing loss in post-mortem tissue. Hearing research 327: 78-88. 
Vuckovic D, Dawson S, Scheffer DI, Rantanen T, Morgan A, Di Stazio M, Vozzi D, Nutile T, 
Concas MP, Biino G et al. 2015. Genome-wide association analysis on normal hearing 
function identifies PCDH20 and SLC28A3 as candidates for hearing function and loss. 
Human molecular genetics 24: 5655-5664. 
Wei J, Hu Y, Zhang L, Hao Q, Yang R, Lu H, Zhang X, Chandrasekar EK. 2017. Hearing 
Impairment, Mild Cognitive Impairment, and Dementia: A Meta-Analysis of Cohort 
Studies. Dement Geriatr Cogn Dis Extra 7: 440-452. 
Wolber LE, Girotto G, Buniello A, Vuckovic D, Pirastu N, Lorente-Canovas B, Rudan I, Hayward 
C, Polasek O, Ciullo M et al. 2014. Salt-inducible kinase 3, SIK3, is a new gene 
associated with hearing. Human molecular genetics 23: 6407-6418. 
 
 
Wong AC, Ryan AF. 2015. Mechanisms of sensorineural cell damage, death and survival in the 
cochlea. Front Aging Neurosci 7: 58. 
Yamasoba T, Lin FR, Someya S, Kashio A, Sakamoto T, Kondo K. 2013. Current concepts in age-
related hearing loss: epidemiology and mechanistic pathways. Hearing research 303: 
30-38. 
Yang CH, Schrepfer T, Schacht J. 2015. Age-related hearing impairment and the triad of 
acquired hearing loss. Front Cell Neurosci 9: 276. 
 
Figure Legends 
Figure 1.  An Integrated Mouse and Human Workflow to Identify ARHL genes. WES, whole 




Table 1. Summary of Genome Wide Association Studies into ARHL 
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DCLK1 (doublecortin Like Kinase 1); PTPRD (protein tyrosine 
phosphatase receptor type delta); GRM8 (metabotropic glutamate 
receptor 8); CMIP (c-Maf inducing protein) 
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Principal Component Analysis 
based on PTA 
>18 
Expression studies 
in a subsequent 
study 
GRM8 in 
Fransen et al 
(2014) 
Nolan et al. (2013) ESRRG (Estrogen-related receptor gamma) QTA 3,900 British 
Logistic regression analysis of 
hearing thresholds at 1 and 4 kHz 
44-45 
Esrrg in HC, SC; 
Esrrg-/- mice have a 




Fransen et al (2014) 
ACVR1B (Activin receptor type-1B);  
CCBE1 (Collagen and Calcium Binding EGF Domains 1) 
QTA 2,161 Belgian 
Principal Component Analysis 
based on PTA 
53-67 None None to date 
Wolber et al. (2014) SIK3 (salt-inducible kinase 3) Meta 4,939 
European, 
Silk Road 
Principal Component Analysis 
based on PTA 
18-98 
Expression of Sik3 
in stria, HC and 
SGN 
None to date 
Vuckovic et al. (2014) 
PCDH20 (Protocadherin 20);  













within study  
Hoffman et al. (2016) 
ISG20 (Interferon-stimulated gene 20 kDa protein);  
TRIOBP (TRIO And F-Actin Binding Protein);  
ILDR1 (Immunoglobulin Like Domain Containing Receptor 1);  








Diagnosis of ARHL related 













aGenome wide significance indicated in bold, defined here as p<5x10-8; bReplication of association at gene level, not necessarily at SNP level 
PTA, pure tone audiogram; HC, hair cells; SC, supporting cells; SGN, spiral ganglion neurons; Ca:Co, Case Control; QTA, Quantitative Trait Analysis; Meta, Meta-
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